Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)

Genentech announced that its investigational medicine, fenebrutinib, is the first in over a decade to show a reduction in disability progression in primary progressive multiple sclerosis (PPMS). In the Phase III FENtrepid study, fenebrutinib met its primary endpoint of non-inferiority to Ocrevus, reducing the risk of disability progression by 12%. The drug also demonstrated potential benefits in upper limb function. Regulatory submission for fenebrutinib is planned following the upcoming Phase III FENhance 1 readout, expected in mid-2026.